Welcome to our dedicated page for RLFFD news (Ticker: RLFFD), a resource for investors and traders seeking the latest updates and insights on RLFFD stock.
RELIEF THERAPEUTICS Holding SA (RLFFD) is a biopharmaceutical company focused on delivering innovative treatment options for select specialty and rare diseases. With a commitment to advancing treatment paradigms, the company's portfolio includes marketed products, proprietary platform technologies, and a clinical development pipeline targeting rare metabolic, dermatology, and respiratory diseases. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases, supported by an experienced team of biopharma industry leaders.
Rhea-AI Summary
RELIEF THERAPEUTICS reports financial results for H1 2023, positive corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential for an additional $46.5 million in milestone and royalty payments. The transition to a revenue-based royalty stream model is expected to deliver earlier returns and enhanced predictability to Relief Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Relief Therapeutics announces the results of its Annual General Meeting (AGM) of shareholders. Certain proposed items by the board of directors did not receive majority approval, possibly due to differences in opinion on the future development of the company. The rejected proposals will be reviewed and analyzed. The AGM approved the annual report and financial statements for 2022, but denied discharge to the board of directors and executive committee for their activities in 2022. The capital band and conditional share capital remain unchanged. Most proposed amendments to the Articles of Association were approved, except for compensation-related amendments. Compensation proposals for board members and the executive committee were rejected. Existing board members were re-elected, including Dr. Raghuram Selvaraju as chairman. The nomination and compensation committee, independent voting rights representative, and auditors were also re-elected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the market cap of RLFFD (RLFFD)?
The market cap of RLFFD (RLFFD) is approximately 47.4M.
What is RELIEF THERAPEUTICS Holding SA focused on?
RELIEF THERAPEUTICS Holding SA is focused on delivering innovative treatment options for select specialty and rare diseases.
What does the company's portfolio consist of?
The company's portfolio includes marketed products, proprietary platform technologies, and a clinical development pipeline targeting rare metabolic, dermatology, and respiratory diseases.
What is RELIEF THERAPEUTICS' mission?
RELIEF THERAPEUTICS' mission is to provide therapeutic relief to those suffering from rare diseases.
Where is RELIEF THERAPEUTICS headquartered?
RELIEF THERAPEUTICS is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany, and Monza, Italy.
What is the stock symbol for RELIEF THERAPEUTICS?
The stock symbol for RELIEF THERAPEUTICS is RLFFD.
Where can I find more information about RELIEF THERAPEUTICS?
You can visit RELIEF THERAPEUTICS' website at www.relieftherapeutics.com or follow them on LinkedIn and Twitter.
RLFFD
OTC:RLFFD
RLFFD Rankings
RLFFD Stock Data
47.44M